Post by Paul Taylor on Sept 3, 2014 4:58:02 GMT -8
Introducing myself - my name is Paul Taylor, diagnosed in July 2011 at age 41 with metastatic PCa. No Gleason score, due to being diagnosed via lymph node dissection; no primary tumor identified via core biopsy, ultrasound, or endorectal MRI. PSA at diagnosis was 80, with metastasis to retro peritoneal and pelvic LNs. No known bone metastasis.
Upon diagnosis, started ADT3 (Lupron/Casodex/Avodart); later added Zytiga/Prednisone and early-course chemo (6 rds of Taxotere/Carboplatin). Slow PSA decline to 4.1 over one year, with resolution of all LN activity. RALP/LND in July 2012, resulting in PSA decrease to 1.1, while continuing on Lupron/Casodex/Zytiga/Prednisone.
In October 2012, PSA increased over two months to 3.5; new, single LN activity in left psoas muscle. Discontinued Casodex, with no effect. Switched from Zytiga to Xtandi in December 2012; gradual PSA decrease with radiological resolution of LN activity.
Provenge in February-March 2013. Continued PSA decrease to 0.02 at present. Remain on Lupron and Xtandi.
Am in the Army, stationed in Washington, DC. Have been active as a peer counselor at MD Anderson, as well as an advocate locally with ZERO, a prostate cancer advocacy group. Am also approved to participate as a peer reviewer in the next round of the CDMRP Prostate Cancer program with DoD (given my active duty status). Am also attending the PCRI conference this weekend in LA - hope to meet some of you all there.
Paul
Upon diagnosis, started ADT3 (Lupron/Casodex/Avodart); later added Zytiga/Prednisone and early-course chemo (6 rds of Taxotere/Carboplatin). Slow PSA decline to 4.1 over one year, with resolution of all LN activity. RALP/LND in July 2012, resulting in PSA decrease to 1.1, while continuing on Lupron/Casodex/Zytiga/Prednisone.
In October 2012, PSA increased over two months to 3.5; new, single LN activity in left psoas muscle. Discontinued Casodex, with no effect. Switched from Zytiga to Xtandi in December 2012; gradual PSA decrease with radiological resolution of LN activity.
Provenge in February-March 2013. Continued PSA decrease to 0.02 at present. Remain on Lupron and Xtandi.
Am in the Army, stationed in Washington, DC. Have been active as a peer counselor at MD Anderson, as well as an advocate locally with ZERO, a prostate cancer advocacy group. Am also approved to participate as a peer reviewer in the next round of the CDMRP Prostate Cancer program with DoD (given my active duty status). Am also attending the PCRI conference this weekend in LA - hope to meet some of you all there.
Paul